North Immunology is taking the reverse-merger route to reach the public markets, combining with Aethlon Medical in a deal that would provide about $180 million for its long-acting inflammation and immunology program. The company’s lead asset is designed for eczema, positioning its bispecific approach against existing immune disorder therapies.